(Q43882042)

27 November 2017

Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome (English)

1 reference

27 November 2017

1 reference

1 reference

11

1 reference

27 November 2017

12

1 reference

27 November 2017

Christopher S Foster

1

1 reference

27 November 2017

Alison Falconer

2

1 reference

27 November 2017

Andrew R Dodson

3

1 reference

27 November 2017

Andrew R Norman

4

1 reference

27 November 2017

Nening Dennis

5

1 reference

27 November 2017

Anne Fletcher

6

1 reference

27 November 2017

Christine Southgate

7

1 reference

27 November 2017

Anna Dowe

8

1 reference

27 November 2017

David Dearnaley

9

1 reference

27 November 2017

Sameer Jhavar

10

1 reference

27 November 2017

Colin S Cooper

13

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

27 November 2017

1 reference

27 November 2017

23

1 reference

27 November 2017

5871-5879

1 reference

27 November 2017

35

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207800

27 November 2017

0 references

cites work

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Amplification and overexpression of E2F3 in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Gene expression phenotypic models that predict the activity of oncogenic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

DNA hypermethylation status of multiple genes in prostate adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Abnormal expression of MDM2 in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

E2F3 activity is regulated during the cell cycle and is required for the induction of S phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

p19ARF targets certain E2F species for degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

The E2F1-3 transcription factors are essential for cellular proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

inferred from DOI database lookup

7 January 2021

based on heuristic

Pathology of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

inferred from DOI database lookup

7 January 2021

based on heuristic

G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207800

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1207800

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference